Catalyst Pharmaceuticals (CPRX) EPS (Weighted Average and Diluted) (2018 - 2026)

Catalyst Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 9 years, with the latest figure at $0.5 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 11.11% year-over-year to $0.5; the trailing twelve-month figure through Mar 2026 stood at $1.74 (up 10.83% YoY), and the FY2025 full-year result was $1.68, up 28.24% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at $0.5, up from $0.41 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $0.5 in Q1 2026, with the low at -$0.29 in Q3 2023.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.29 across 5 years, with a median of $0.33 in 2023.
• Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) tumbled 245.0% — and 2024, when it jumped 220.69%.
• Catalyst Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.23 in 2022, then soared by 34.78% to $0.31 in 2023, then surged by 41.94% to $0.44 in 2024, then decreased by 6.82% to $0.41 in 2025, then rose by 21.95% to $0.5 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.5 (Q1 2026), $0.41 (Q4 2025), and $0.42 (Q3 2025), per Business Quant data.